Cellectis Licenses TAL Technology from Iowa State | GenomeWeb

NEW YORK (GenomeWeb News) – Cellectis today announced two licensing agreements with Iowa State University granting the Paris-based genome engineering firm the rights to use inventions related to TAL effector-nucleases and monomeric TALENs.

The licenses allow Cellectis to use the technology in any field, it said. TALENs are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest in any species.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, the New York Times reports.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.